List of Armonair Digihaler drug patents

Armonair Digihaler is owned by Teva Pharm.

Armonair Digihaler contains Fluticasone Propionate.

Armonair Digihaler has a total of 47 drug patents out of which 0 drug patents have expired.

Armonair Digihaler was authorised for market use on 27 January, 2017.

Armonair Digihaler is available in powder;inhalation dosage forms.

The generics of Armonair Digihaler are possible to be released after 22 August, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7540282 TEVA PHARM Reservoir pressure system for medicament inhaler
May, 2023

(3 months from now)

US7540282

(Pediatric)

TEVA PHARM Reservoir pressure system for medicament inhaler
Nov, 2023

(9 months from now)

US9616024 TEVA PHARM Process for preparing a medicament
Sep, 2024

(1 year, 6 months from now)

US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament
Mar, 2025

(2 years from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(2 years from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus
May, 2025

(2 years from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(2 years from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Nov, 2025

(2 years from now)

US8651103 TEVA PHARM Dry powder inhalation apparatus
Mar, 2028

(5 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Sep, 2028

(5 years from now)

US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(8 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(8 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(8 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(8 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(8 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(8 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(8 years from now)

US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(9 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(9 years from now)

US9782551 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US9782550 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(12 years from now)

US10918816 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(12 years from now)

US9782550

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(13 years from now)

US9782551

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2036

(13 years from now)

US10918816

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Jun, 2036

(13 years from now)

US10569034 TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(13 years from now)

US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler
Feb, 2037

(14 years from now)

US11351317 TEVA PHARM Drug delivery device with electronics
Feb, 2038

(15 years from now)

US11351317

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Aug, 2038

(15 years from now)

US11357935 TEVA PHARM Drug delivery device with electronics
Sep, 2038

(15 years from now)

US11000653 TEVA PHARM Inhaler
Dec, 2038

(15 years from now)

US11000653

(Pediatric)

TEVA PHARM Inhaler
Jun, 2039

(16 years from now)

US11344685 TEVA PHARM Drug delivery device with electronics
Sep, 2039

(16 years from now)

US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(17 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(17 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(17 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(17 years from now)

US11173259

(Pediatric)

TEVA PHARM Drug delivery device with electronics and power management
Jan, 2041

(17 years from now)

US11266796 TEVA PHARM Inhalation device with integrated electronics
Feb, 2041

(18 years from now)

US11266796

(Pediatric)

TEVA PHARM Inhalation device with integrated electronics
Aug, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic